Heron Therapeutics Inc (NASDAQ:HRTX) was down 5.5% on Tuesday . The stock traded as low as $22.30 and last traded at $22.50. Approximately 606,569 shares traded hands during trading, a decline of 38% from the average daily volume of 976,473 shares. The stock had previously closed at $23.80.
Several equities research analysts recently weighed in on HRTX shares. Mizuho restated a “buy” rating and set a $28.00 target price on shares of Heron Therapeutics in a research note on Tuesday, January 16th. ValuEngine upgraded Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. Leerink Swann started coverage on Heron Therapeutics in a research note on Tuesday, January 2nd. They set an “outperform” rating and a $22.00 target price for the company. Cowen restated a “buy” rating and set a $40.00 target price on shares of Heron Therapeutics in a research note on Wednesday, December 6th. Finally, Zacks Investment Research upgraded Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 8th. Two equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Heron Therapeutics currently has an average rating of “Buy” and a consensus price target of $29.92.
The company has a current ratio of 2.12, a quick ratio of 2.02 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $1,230.00, a P/E ratio of -5.94 and a beta of 1.87.
In other Heron Therapeutics news, VP Kimberly Manhard sold 7,584 shares of the business’s stock in a transaction that occurred on Wednesday, January 10th. The stock was sold at an average price of $20.00, for a total value of $151,680.00. Following the completion of the sale, the vice president now owns 7,584 shares in the company, valued at $151,680. The sale was disclosed in a document filed with the SEC, which is available through this link. 19.93% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the business. Ellington Management Group LLC purchased a new stake in Heron Therapeutics in the fourth quarter valued at approximately $195,000. Pinnacle Associates Ltd. purchased a new stake in Heron Therapeutics in the fourth quarter valued at approximately $201,000. Trexquant Investment LP purchased a new stake in Heron Therapeutics in the third quarter valued at approximately $206,000. Jefferies Group LLC purchased a new stake in Heron Therapeutics in the fourth quarter valued at approximately $214,000. Finally, Jane Street Group LLC purchased a new stake in Heron Therapeutics in the third quarter valued at approximately $223,000.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by Stock Observer and is the sole property of of Stock Observer. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.thestockobserver.com/2018/02/20/heron-therapeutics-hrtx-shares-down-5-5.html.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.